6-K - Genmab A/S | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Genmab A/S filed Exhibit 3.1, an English translation of its Articles of Association dated March 19, 2026, confirming share capital of DKK 64,250,721 and Board of Directors authorizations for capital increases up to DKK 6,600,000 without or with pre-emption rights until March 12, 2029, employee warrants under three programs up to DKK 750,000 each, and convertible debt instruments up to DKK 3,000,000 new shares.

Key Takeaways

1Share capital equals DKK 64,250,721 divided into DKK 1 shares.

2Board authorized to increase share capital without pre-emption rights by up to DKK 6,600,000 until March 12, 2029.

3Board authorized to increase share capital with pre-emption rights by up to DKK 6,600,000 until March 12, 2029, total max DKK 6,600,000.

4Warrant authorization from April 13, 2021: up to DKK 750,000; issued 750,000 warrants and re-issued 104,194; expires April 12, 2026.

5Warrant authorization from March 13, 2024: up to DKK 750,000; issued 750,000 warrants and re-issued 30,310; expires March 12, 2029.

6Warrant authorization from March 12, 2025: up to DKK 750,000; issued 33,515 warrants; expires March 11, 2030.

7Board authorized to issue convertible debt instruments convertible to up to DKK 3,000,000 new shares until March 12, 2029.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (2)

3.1

EX-3.1

6-K